Home » Stocks » CBLI

Cleveland BioLabs, Inc. (CBLI)

Stock Price: $4.89 USD -0.06 (-1.21%)
Updated Apr 22, 2021 4:00 PM EDT - Market closed
Market Cap 76.11M
Revenue (ttm) 262,942
Net Income (ttm) -2.40M
Shares Out 15.47M
EPS (ttm) -0.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 22
Last Price $4.89
Previous Close $4.95
Change ($) -0.06
Change (%) -1.21%
Day's Open 4.95
Day's Range 4.75 - 5.08
Day's Volume 89,523
52-Week Range 1.43 - 10.97


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

The substantially improved pharmacological profile of GP532 opens new opportunities for broader therapeutic applications of this class of pharmaceuticals BUFFALO, NY / ACCESSWIRE / April 14, 2021 / Geno...

1 week ago - Accesswire

NEW YORK, March 12, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights o...

Other stocks mentioned: AKER, TLRY
1 month ago - PRNewsWire

FORT COLLINS, Colo. and BUFFALO, N.Y., Feb. 17, 2021 /PRNewswire/ -- Cleveland BioLabs, Inc. (NASDAQ: CBLI), an innovative biopharmaceutical company developing novel approaches to activate the immune sy...

2 months ago - PRNewsWire

NEW YORK, Dec. 28, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Cleveland BioLabs, Inc. (NASDAQ: CBLI) concerning pote...

3 months ago - PRNewsWire

NEW YORK, Oct. 21, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cleveland BioLabs, Inc. ("CBLI" or the ...

6 months ago - PRNewsWire

NEW YORK, Oct. 21, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Cleveland BioLabs, Inc. (NASDAQ: CBLI) and its board of directors concerning the proposed ...

6 months ago - PRNewsWire

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Cytocom, Inc. is fair to Cleveland ...

6 months ago - Business Wire

New York, New York--(Newsfile Corp. - October 20, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Cleveland BioLabs, Inc. ("BioLabs" or...

6 months ago - Newsfile Corp

Shares of nano-cap Cleveland BioLabs, Inc. (NASDAQ: CBLI) jumped out of the gate at Monday's open and are sustaining the strong momentum on over 100 times their average volume.

1 year ago - Benzinga

Airlines, hotels, casinos and stocks linked to Wuhan, China, continue to fall as fear of the coronavirus deters international travel and all but halts activity in the virus epicenter.

Other stocks mentioned: AEMD, APT, AZN, BCRX, CERS, CODX, INO ...
1 year ago - Benzinga

About CBLI

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and immuno-oncology. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a reco... [Read more...]

IPO Date
Jul 21, 2006
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

In 2020, CBLI's revenue was $262,942, a decrease of -76.38% compared to the previous year's $1.11 million. Losses were -$2.40 million, -9.39% less than in 2019.

Financial Statements